Multimodality Treatment of Neuroendocrine Tumors of the Thymus

Abstract

Background: Neuroendocrine tumors of the thymus are rare neoplasms. Four patients with this tumor who underwent multimodality treatment are presented and the literature is briefly reviewed. Methods: The medical records of all patients treated for neuroendocrine tumors of the thymus from 1979 to 2002 were reviewed. Tumors were classified using a slight modification of the World Health Organization criteria. Results: The patients' median age was 38 years. All patients underwent extensive excision of the tumor. Histological diagnosis was atypical carcinoid (2), typical carcinoid (1), and small cell carcinoma (1). All patients developed recurrence(s). One patient died 132 months after diagnosis. The remaining three patients are alive with no symptoms at 135, 99, and 35 months, respectively, after diagnosis. Two patients with recurrences have been on treatment with Octreotide LAR® with satisfactory results. One patient is free of disease. Conclusions: Neuroendocrine tumors of the thymus are potentially aggressive tumors. Radical resection is the treatment of choice. The encouraging results obtained by administration of Octreotide LAR® in two of our patients warrant further investigation.

Key words

Mediastinum - carcinoid - Octreotide - recurrence - thymus

References

• 1 Chaer R, Massad M G, Evans A, Snow N J, Geha A S. Primary neuroendocrine tumors of the thymus.  Ann Thorac Surg. 2002;  74 1733-1740
• 2 Rosai J, Higa E, Davie J. Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis: a previously unrecognized association.  Cancer. 1972;  29 1075-1083
• 3 Rosai J, Sobin L H. World Health Organization International Histological Classification of Tumors: Histological Typing of Tumors of the Thymus. 2nd ed. Berlin; Springer Verlag 1999: 15-18
• 4 Klemm K, Moran C. Primary neuroendocrine carcinomas of the thymus.  Semin Diagn Pathol. 1999;  16 32-41
• 5 Floros D, Dosios T, Tsourdis A, Yiatromanolakis N. Carcinoid tumor of the thymus with multiple endocrine adenomatosis.  Path Res Pract. 1982;  175 404-409
• 6 De Perrot M, Spiliopoulos A, Fischer S, Totsch M, Keshavjee S. Neuroendocrine carcinoma (carcinoid) of the thymus associated with Cushing's syndrome.  Ann Thorac Surg. 2002;  73 675-681
• 7 Moran C, Suster S. Neuroendocrine carcinomas (carcinoid tumors) of the thymus. A clinicopathologic analysis of 80 cases.  Am J Clin Pathol. 2000;  114 100-110
• 8 Brown L R, Aughenbaugh G L, Wick M R, Baker B A, Salassa R M. Roentgenologic diagnosis of primary corticotropin-producing carcinoid tumors of the mediastinum.  Radiology. 1982;  142 143-148
• 9 Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties.  Ann Thorac Cardiovasc Surg. 1999;  5 285-292
• 10 Lokich J J, Li F. Carcinoid tumor of the thymus with hereditary hyperparathyroidism.  Ann Intern Med. 1978;  89 364-365
• 11 Marchevsky A M, Dikman S H. Mediastinal carcinoid with an incomplete Sipple's syndrome.  Cancer. 1979;  43 2497-2501
• 12 Wick M R, Rosai J. Neuroendocrine neoplasms of the thymus.  Path Res Pract. 1988;  183 188-189
• 13 John L CH, Hornick P, Lang S, Wallis J, Edmondson S J. Giant thymic carcinoid.  Postgrad Med J. 1991;  67 462-465
• 14 Economopoulos G C, Lewis J W, Lee M W, Silverman N A. Carcinoid tumors of the thymus.  Ann Thorac Surg. 1990;  50 58-61
• 15 Gal A A, Kornstein M J, Cohen C, Duerte I G, Miller J I, Mansour K. Neuroendocrine tumors of the thymus: A clinicopathological and prognostic study.  Ann Thorac Surg. 2001;  72 1179-1182
• 16 Arnond R, Simon B, Wied M. Treatment of neuroendocrine GEP tumors with somatostatin analogues.  Digestion. 2000;  62 (Suppl) S84-S91
• 17 Errikson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumours.  Ann Oncol. 1999;  10 (Suppl) S31-S38
• 18 Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.  Ann Oncol. 2001;  12 (Suppl) S111-S114
• 19 Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumors with octreotide LAR.  Aliment Pharmacol Ther. 2000;  14 557-560
• 20 Filosso P L, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoid with liver metastases, treated with octreotide.  Eur J Cardiothorac Surg. 2002;  21 913-917
• 21 Filosso P L, Dato G MA, Ruffini E, Bretti S, Ozzello F, Mancuso M. Multidisciplinary treatment of advanced neuroendocrine carcinoma (carcinoid): Report of a successful case and review of the literature.  J Thorac Cardiovasc Surg. 2004;  127 1215-1219